Coverage Discontinued On ZymoGenetics

Piper Jaffray has published a report on ZymoGenetics, Inc.

announcing that it has discontinued coverage as ZymoGenetics has been acquired by Bristol-Myers Squibb

, a deal that was completed yesterday. In the report, Piper Jaffray writes "Investors should no longer rely on our last published rating, price target, model, or estimates on ZymoGenetics as they will not be updated following the discontinuation of coverage date." ZymoGenetics closed yesterday at $9.76.